



CORPORATE PROFILE 2025



TAISHO PHARMACEUTICAL CO., LTD.

Introduction

Your health is our specialty.



To prevent illness and promote healthier living.

With these goals in mind, Taisho Pharmaceutical was founded
in the first year of the Taisho era (1912).

For over **100 years**, we have been contributing to the realization of healthy and
affluent lives by offering a wide range of products,
from disease prevention to treatment, to meet the diverse needs of consumers.

In recent years, the environment surrounding the pharmaceutical industry has changed
significantly, and consumers' needs have diversified as health awareness has grown.

Taisho Pharmaceutical is committed to responding flexibly to these changes while
continuing to provide high-quality products and services

so that we can support our consumers' health.

Self-Medication Business

As a leading company in Japan's OTC pharmaceutical market, we offer approximately 40 brands through our domestic self-medication business, including OTC drugs sold at drugstores and pharmacies, as well as health-related products such as health foods and skincare products. We provide a range of products with various therapeutic effects, including category-leading brands like *Lipovitan*, *Pabron*, and *RiUP*.

In recent years, in response to changes in consumer purchasing behavior, such as the shift to online channels, we have been focusing on two mail-order sales channels, Taisho Pharmaceutical Direct and TAISHO BEAUTY ONLINE, to improve convenience.

Pharmaceuticals and quasi-drugs



TOPICS

alli : Japan's First Visceral Fat Reduction Drug!

In recent years, changes in dietary habits and other factors have caused a sharp increase in lifestyle-related diseases. Among these, the excessive accumulation of visceral fat poses a risk of developing conditions such as diabetes and hypertension, making self-medication more important than ever. Since its founding, our company has held fast to its desire to prevent disease and promote health, so we committed ourselves to addressing this issue and supporting at-risk individuals. Despite many challenges, we remained steadfast in our beliefs, and after 14 years of development, we are proud to bring *alli* to the market. Moving forward, we will continue striving to accurately ascertain the evolving needs of consumers and deliver excellent products that satisfy them.



Health foods



Beauty



Prescription Pharmaceutical Business

As an R&D-oriented company, we are engaged in drug discovery through in-house development efforts and have developed and launched the macrolide antibiotic *Clarith*, the SGLT2 inhibitor *Lusefi*, the transdermal anti-inflammatory analgesic patch formulation *LOQOA*, and the anti-TNF α inhibitor *Nanozora*.

Currently, we are aiming to discover drugs that address unmet medical needs. To accelerate the approval process for our in-house developed products and expand our pipeline, we are focusing on R&D to diversify our modalities, while working to introduce new technologies and co-development in collaboration with external research institutions and partnerships between industry, government, and academia.




International Business

In our international business, we are expanding mainly in Southeast Asian and European markets with the aim of actively entering regions where future growth is expected. In Southeast Asia, we have been strengthening our business foundation and cultivating OTC drug brands acquired through M&A and brand acquisitions. In Europe, we are expanding our business mainly in France by leveraging the strong foundation of UPSA, a wholly owned subsidiary since 2019.

In addition to OTC drugs and *Lipovitan*, we sell a wide range of products, including health foods and beauty products, in more than 80 countries through our overseas subsidiaries. We will continue to respond to the health needs of each country while leveraging the business model we have developed in Japan.



Overseas areas where we do business



To Deliver Safe, Reliable, High-Quality Products

France

Gascogne Plant
Guyenne Plant

Japan

Omiya Plant
Hanyu Plant
Okayama Plant
Kobe Plant
Miyashiro Plant

China

Shanghai Plant

Vietnam

Nha Trang Plant
Tan Phu Thanh Plant
Nguyen Van Cu Plant

Malaysia

Bangi Plant
Klang Plant

Indonesia

Depok Plant

Production

Collaborating domestically
and internationally and
sharing know-how

Taisho Pharmaceutical produces safe and reliable products that meet consumer expectations through strict quality control and production in a hygienic environment. In addition, we have established our own management standards to prevent environmental pollution, including both air and water pollution, and engage in production activities that consider the social environment.


As a global pharmaceutical company, we develop a variety of product lines both in Japan and overseas. To strengthen our production system, we provide various forms of support from our flagship Omiya Plant to our other plants in Japan and abroad, including personnel dispatch, technical guidance, and quality control instruction.

Quality

Producing products that
everyone can trust

Taisho Pharmaceutical complies with all relevant laws and regulations in all operations to fulfill its social responsibility as a pharmaceutical company and to contribute to the realization of healthy and affluent lives for consumers. In addition, we prioritize ensuring the efficacy, safety, and reliability of our products by sincerely listening to consumer feedback and applying it to safety management and quality improvement.

We have established procedures and provide training to those involved in post-marketing safety management and quality control to ensure a rapid response to unexpected adverse events or quality issues. We mitigate risks by closely monitoring adverse events and quality complaints related to our products, and by minimizing the impact of incidents when they occur through measures such as rapid product recalls.



Relationship with Society



As part of our sustainability initiatives, we are actively communicating with stakeholders, including consumers, suppliers, and employees, while addressing social issues such as environmental problems. We remain committed to fulfilling the social responsibilities and roles expected of corporations, aiming to contribute to the realization of a sustainable society.

Research incentives

The Uehara Memorial Foundation

The Uehara Memorial Foundation was established in 1985 to commemorate the legacy of the late Shokichi Uehara (former president and chairman of Taisho Pharmaceutical), as part of the 70th anniversary of the company's founding. With a commitment to contributing to the advancement of life sciences, the foundation focuses on providing research grants to individuals engaged in life science research, recognizing outstanding achievements, and holding international symposiums.



Sports sponsorships

Sports support for children

We are committed to supporting sports-related activities because we believe that sports contribute to the cultivation of both healthy minds and bodies, and that giving back to the community by reinvesting business profits is a fundamental responsibility for pharmaceutical companies. Our support extends beyond professional athletes, as we also contribute to the development of sports culture through initiatives such as hosting the “ALL BLACKS CLINIC” presented by *Lipovitan D*,” a rugby school for children.



Culture promotion

Uehara Museum of Art

The Uehara Museum of Art exhibits a collection that transcends both Eastern and Western genres, featuring Buddhist art, including statues and ancient manuscripts from the Heian and Kamakura periods, as well as Western art such as Impressionist and modern Japanese paintings. The museum also contributes to the enrichment of local culture through a wide range of cultural activities, including research on Buddhist art in Izu, lectures and workshops by specialists, and educational outreach programs in cooperation with schools.



Company Overview

Name:
Taisho Pharmaceutical Co., Ltd.

Representative:
Shigeru Uehara, Chief Executive Officer

Founding:
October 12, 1912

Establishment:
May 5, 1928

Capital:
29,837 million yen

Address:
3-24-1 Takada, Toshima-ku, Tokyo

Tel:
+81-3-3985-1111

Business Activities

Domestic We research, develop, and market products that meet the health needs of consumers, including OTC drugs sold in drugstores and pharmacies, health foods, and skincare products.

International We are cultivating OTC drugs utilizing local brands and actively launching new products in Southeast Asian and European markets.

Pharmaceutical As an R&D-oriented company, we research, develop, and market prescription pharmaceuticals. In addition to launching in-house developed products, we are also aggressively expanding our pipeline through in-licensing.

Domestic and Overseas Group Companies

Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Co., Ltd.		Biofermin Pharmaceutical Co., Ltd.
Main domestic subsidiaries	Main overseas subsidiaries	
Taisho Pharma Co., Ltd.	UPSA SAS	Taisho Pharmaceutical (H.K.) Ltd.
Taisho Pharmaceutical F.M. Co., Ltd.	Duoc Hau Giang Pharmaceutical JSC	Osotspa Taisho Co., Ltd.
TOKUHON Corporation	Taisho Pharmaceutical (Taiwan) Co., Ltd.	PT. Taisho Pharmaceutical Indonesia Tbk
Taisho Okinawa Co., Ltd.	Taisho Pharmaceuticals (Philippines), Inc.	Taisho Pharmaceutical Singapore Private Limited
MEJIRO KOSAN Co., Ltd.	Taisho Co., Ltd. Shanghai	Hoepharm Holdings Sdn. Bhd.
Taisho Pharmaceutical Logistics Co., Ltd.	Taisho Vietnam Co., Ltd.	Taisho Pharmaceutical (Thailand) Co., Ltd.
Taisho M.T.C. Co., Ltd.		
TAISHO ACTIVE HEALTH Co., Ltd.		



TAISHO PHARMACEUTICAL CO., LTD.